Colin Hill Keynote at Servier Paris-Saclay R&D Institute in France
On July 20th, we had the privilege to visit the cutting-edge Servier Paris-Saclay R&D Institute in France, where our CEO, Colin Hill delivered a keynote titled: “Why AI and Digital Twins will Drive the Discovery and Development of the Next Generation of Breakthrough Drugs“. The open conference was a remarkable display of Servier’s dedication to foster a collaborative […]
FierceBiotech features Alexion-GNS Partnership Targeting Rare Diseases
Alexion inks genomics pacts to continue R&D reboot August 11, 2017 – Alexion has teamed up with GNS Healthcare and Sema4 to advance its rare disease R&D agenda. The partnerships give Alexion access to modeling and simulation software used by Celgene and a partner to support its push into genomics. Read the full article here. […]
GNS Prominently Featured in BioCentury Cover Story on Use of Machine Learning by Pharma
Applying machine learning tools to drug R&D could usher in a new era of effective therapies targeting causative disease drivers, higher success rates in clinical trials and real world tools to manage adherence, prevent adverse events and reduce total healthcare costs. Download the complete article here.